Embecta Corp. Common Stock (EMBC) Stock Price
EMBCStock
$6.27−54.20%52W
Market Cap$355.26M
P/E3.72x
PEG Ratio—
Div yield3.43%
Beta0.86
EMBC Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-43.63%
Price vs S&P 500 (4W)19.63%
VGM Score56.79
P/E Ratio (Annual)3.72x
Indicated Dividend Yield (Annual)3.43%
EMBC Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.27 | $0.56 | +111.32%(+$0.30) | |
| Q1 2026 | $0.42 | $0.27 | -35.33%(-$0.15) | |
| Q4 2025 | $0.67 | $0.71 | +5.97%(+$0.04) | |
| Q3 2025 | $0.46 | $0.50 | +9.89%(+$0.04) | |
| Q2 2025 | $0.78 | $1.12 | +44.52%(+$0.35) |
EMBC Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
2.33
2.33
2.33
2.33
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
EMBCEmbecta Corp. Common Stock | A | F | B | 0.3x | -0.1% | 59.0% | 21.9% | $6.27 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About Embecta Corp. Common Stock
Embecta Corp manufactures diabetes care products including insulin pen needles, syringes, and safety devices sold through wholesalers and distributors, with the majority of revenue from the United States. The company also offers a proprietary digital application for diabetes management and provides contract manufacturing services.